Art. -Nr.: HY-13770

Copy Link Print Information

Troxacitabine

(Synonyms: BCH 4556; L-OddC; SPD 758)

Kundenbewertung

Based on 1 Customer Validation

Troxacitabine is nucleoside analog with potent anticancer activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.95%
CAS. Nr.: 145918-75-8
Formel: C₈H₁₁N₃O₄
Molecular Weight:213.19

Speicherung:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Troxacitabine Chemical Structure

CAS. Nr.: 145918-75-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Troxacitabine is nucleoside analog with potent anticancer activity.

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.68 μM Compound: 5	Cytotoxicity against A549 cells after 72 hrs by SRB assay Cytotoxicity against A549 cells after 72 hrs by SRB assay	[PMID: 17419604]
CCRF-CEM	IC₅₀	>1 μM Compound: beta-L-cytosine	Compound was evaluated for cytotoxicity by inhibition of mitochondrial DNA synthesis Compound was evaluated for cytotoxicity by inhibition of mitochondrial DNA synthesis	10.1016/0960-894X(95)00343-R
CCRF-CEM	IC₅₀	0.056 μM Compound: beta-L-cytosine	Cytotoxicity in H1 CEM cells Cytotoxicity in H1 CEM cells	10.1016/0960-894X(95)00343-R
Hepatoma cell line	EC₅₀	0.0005 μM Compound: beta-L-cytosine	Antiviral activity against hepatitis B virus in human hepatoma cell line (2.2.15 cells) Antiviral activity against hepatitis B virus in human hepatoma cell line (2.2.15 cells)	10.1016/0960-894X(95)00343-R
Hepatoma cell line	EC₅₀	0.5 nM Compound: beta-L-cytosine	Antiviral activity against hepatitis B virus in human hepatoma cell line (2.2.15 cells) Antiviral activity against hepatitis B virus in human hepatoma cell line (2.2.15 cells)	10.1016/0960-894X(95)00343-R
SW1573	IC₅₀	2.3 μM Compound: 5	Cytotoxicity against SW1573 cells after 72 hrs by SRB assay Cytotoxicity against SW1573 cells after 72 hrs by SRB assay	[PMID: 17419604]
Vero	IC₅₀	0.1 μM Compound: 25	Cytotoxic effect against vero cells. Cytotoxic effect against vero cells.	[PMID: 8496934]

In Vitro

Troxacitabine has shown cutotoxicity in cancer cell lines of hepatocellular (HepG2), prostate (PC3, DUI45), non-small cell lung (NCI-H460, NCr-322M) colon (HT29), renal (CAK-l, A498, RXF-393, SNI2-C) and pancreatic origin (Pnac-Ol, MiaPa Ca) with IC₅₀s range from 15-35 μM^[1]^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Troxacitabine is highly active against the Panc-01 model, with TGI levels of 88.5% and 84.3% at the 10 and 25 mg/kg doses, respectively. The mean final tumor weights for animals given troxacitabine are also significantly smaller compared with vehicle controls. Troxacitabine has less activity against the MiaPaCa model^[3]. Troxacitabine is very effective in human RCC tumor xenograft models, including CAM-i, A498, RXF-393, and SN12C carcinomas. Very good responses are ob served in animals bearing CAM-i, A498, and RXF-393 RCC tumors given i.p. doses of 10, 25, and 50 mg/kg twice a day for 5 days^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 145918-75-8
Appearance Solid
Molecular Weight 213.19
Formel C₈H₁₁N₃O₄
Color White to off-white
SMILES

NC1=NC(N(C=C1)[C@@H]2CO[C@H](CO)O2)=O
Synonyms

BCH 4556; L-OddC; SPD 758
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 20 mg/mL (93.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.6907 mL

23.4533 mL

46.9065 mL

5 mM

0.9381 mL

4.6907 mL

9.3813 mL

10 mM

0.4691 mL

2.3453 mL

4.6907 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Protokoll

Animal Administration^[3]

Mice^[3]

Troxacitabine is administered i.v. to the animals at doses of 10 and 25 mg/kg on a daily 3 5 regimen. Gemcitabine is used as a positive control. The end points for the study included tumor growth inhibition (TGI), final weight, and the number of partial and complete tumor responses in the animals^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Gourdeau H, et al. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts. Cancer Chemother Pharmacol. 2002 Dec;50(6):490-6. [Content Brief]

[2]. Kadhim SA, et al. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models. Cancer Res. 1997 Nov 1;57(21):4803-10. [Content Brief]

[3]. Weitman S, et al. The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity againstpancreatic human tumor xenografts. Clin Cancer Res. 2000 Apr;6(4):1574-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.6907 mL	23.4533 mL	46.9065 mL	117.2663 mL
	5 mM	0.9381 mL	4.6907 mL	9.3813 mL	23.4533 mL
	10 mM	0.4691 mL	2.3453 mL	4.6907 mL	11.7266 mL
	15 mM	0.3127 mL	1.5636 mL	3.1271 mL	7.8178 mL
	20 mM	0.2345 mL	1.1727 mL	2.3453 mL	5.8633 mL
	25 mM	0.1876 mL	0.9381 mL	1.8763 mL	4.6907 mL
	30 mM	0.1564 mL	0.7818 mL	1.5636 mL	3.9089 mL
	40 mM	0.1173 mL	0.5863 mL	1.1727 mL	2.9317 mL
	50 mM	0.0938 mL	0.4691 mL	0.9381 mL	2.3453 mL
	60 mM	0.0782 mL	0.3909 mL	0.7818 mL	1.9544 mL
	80 mM	0.0586 mL	0.2932 mL	0.5863 mL	1.4658 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Troxacitabine

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Nucleotide Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Troxacitabine

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Nucleotide Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Troxacitabine Related Classifications

HY-13770 Related Classifications